COMMUNIQUÉS West-GlobeNewswire

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
25/03/2026
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 [...]
VIVUS Reinforces QSIVA®’s Clinical Efficacy and Safety in Obesity Management
25/03/2026
— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a [...]
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026
25/03/2026
VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual acuity (BCVA) and Virtual Reality Visual Test (VRVT), sustained through six- [...]
SafeSpace Global to Attend ISC West 2026 to Strengthen Industry Relationships and Expand Strategic Pipeline
25/03/2026
Knoxville, TN., March 25, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corp. (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions, dedicated to safety innovation [...]
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
25/03/2026
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has completed its previously announced exchange offer to each holder of [...]
Jushi Holdings Inc. Announces First Settlement in Ongoing Hemp-Derived THC Litigation
25/03/2026
BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced that its [...]
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
25/03/2026
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront [...]
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
25/03/2026
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its [...]
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
25/03/2026
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing [...]
CDT Equity Inc. Announces Reverse Stock Split
25/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
25/03/2026
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 [...]
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
25/03/2026
FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the [...]
Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
25/03/2026
Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel Flyte’s Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-Leading Safety, [...]
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
25/03/2026
Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company [...]
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
25/03/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
25/03/2026
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financial results and [...]
TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
25/03/2026
European Union Market Expansion Advances with Official Authorization FREDERICK, Md., March 25, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
25/03/2026
Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015 [...]

Pages